[HTML][HTML] Antibiotics that protect the brain
D Secko - CMAJ, 2005 - Can Med Assoc
No therapies currently exist to modulate glutamate-mediated injury through glutamate
transporters. However, Rothstein and colleagues hypothesized that increasing the levels of …
transporters. However, Rothstein and colleagues hypothesized that increasing the levels of …
Antibiotics rescue neurons from glutamate attack
K Tanaka - Trends in molecular medicine, 2005 - cell.com
L-glutamate is the major excitatory neurotransmitter in the brain and is responsible for
normal brain function. However, high glutamate exposure triggers neuronal death, a process …
normal brain function. However, high glutamate exposure triggers neuronal death, a process …
β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression
JD Rothstein, S Patel, MR Regan, C Haenggeli… - Nature, 2005 - nature.com
Glutamate is the principal excitatory neurotransmitter in the nervous system. Inactivation of
synaptic glutamate is handled by the glutamate transporter GLT1 (also known as EAAT2; …
synaptic glutamate is handled by the glutamate transporter GLT1 (also known as EAAT2; …
The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention
AL Sheldon, MB Robinson - Neurochemistry international, 2007 - Elsevier
Extracellular concentrations of the predominant excitatory neurotransmitter, glutamate, and
related excitatory amino acids are maintained at relatively low levels to ensure an …
related excitatory amino acids are maintained at relatively low levels to ensure an …
Neuroprotective potential of ceftriaxone in in vitro models of stroke
J Lipski, CK Wan, JZ Bai, R Pi, D Li, D Donnelly - Neuroscience, 2007 - Elsevier
Astrocytic glutamate transporters are considered an important target for neuroprotective
therapies as the function of these transporters is abnormal in stroke and other neurological …
therapies as the function of these transporters is abnormal in stroke and other neurological …
STAGE 3 clinical trial of ceftriaxone in subjects with ALS (S36. 001)
M Cudkowicz, J Shefner, NEALS Consortium - 2013 - AAN Enterprises
OBJECTIVE: To evaluate the efficacy of ceftriaxone in patients with Amyotrophic Lateral
Sclerosis (ALS). BACKGROUND: ALS is a uniformly progressive and fatal …
Sclerosis (ALS). BACKGROUND: ALS is a uniformly progressive and fatal …
ALS trial raises questions about promising drug
J Couzin - 2007 - science.org
An antibiotic long thought to hold promise for treating neurologic diseases failed
dramatically in a recent clinical trial; this news has sparked a debate about why the drug …
dramatically in a recent clinical trial; this news has sparked a debate about why the drug …
[CITATION][C] Calcium, glutamate, and amyotrophic lateral sclerosis: more evidence but no certainties
PJ Shaw - Annals of neurology, 1999 - Wiley Online Library
Current understanding of the neurodegenerative process in amyotrophic lateral sclerosis
(ALS) is that it is likely to reflect a complex interaction between genetic factors, oxidative …
(ALS) is that it is likely to reflect a complex interaction between genetic factors, oxidative …
The boon and bane of radiocarbon dating
TP Guilderson, PJ Reimer, TA Brown - Science, 2005 - science.org
362 ture of many neurological disorders including stroke, spinal cord injury, and ALS (2).
Excitotoxicity is one of the best links between the rare familial form of ALS (caused by …
Excitotoxicity is one of the best links between the rare familial form of ALS (caused by …
Harmine, a natural beta-carboline alkaloid, upregulates astroglial glutamate transporter expression
Glutamate is the predominant excitatory amino acid neurotransmitter in the mammalian
central nervous system (CNS). Glutamate transporter EAAT2/GLT-1 is the physiologically …
central nervous system (CNS). Glutamate transporter EAAT2/GLT-1 is the physiologically …